Literature DB >> 11266650

[3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors.

X Ji1, Y C Kim, D G Ahern, J Linden, K A Jacobson.   

Abstract

MRS 1754 [N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy]acetamide] is a selective antagonist ligand of A(2B) adenosine receptors. This is the least well-defined adenosine receptor subtype, and A(2B) antagonists have potential as antiasthmatic drugs. For use as a radioligand, MRS 1754, a p-cyanoanilide xanthine derivative, was tritiated on the propyl groups in a two-step reaction using a p-carboxamido precursor, which was dehydrated to the cyano species using trifluoroacetic anhydride. [3H]MRS 1754 (150 Ci/mmol) bound to recombinant human A(2B) adenosine receptors in membranes of stably transfected HEK-293 cells. Specific binding was saturable, competitive, and followed a one-site model, with a K(D) value of 1.13 +/- 0.12 nM and a B(max) value of 10.9 +/- 0.6 pmol/mg protein. Specific binding utilizing 0.7 nM [3H]MRS 1754 was > 70% of total binding. The affinity calculated from association and dissociation binding constants was 1.22 nM (N = 4). Binding to membranes expressing rat and human A(1) and A(3) adenosine receptors was not significant, and binding in membranes of HEK-293 cells expressing human A(2A) receptors was of low affinity (K(D) > 50 nM). The effects of cations and chelators were explored. Specific binding was constant over a pH range of 4.5 to 6.5, with reduced binding at higher pH. The pharmacological profile in competition experiments with [3H]MRS 1754 was consistent with the structure-activity relationship for agonists and antagonists at A(2B) receptors. The K(i) values of XAC (xanthine amine congener) and CPX (8-cyclopentyl-1,3-dipropylxanthine) were 16 and 55 nM, respectively. NECA (5'-N-ethylcarboxamidoadenosine) competed for [3H]MRS 1754 binding with a K(i) of 570 nM, similar to its potency in functional assays. Thus, [3H]MRS 1754 is suitable as a selective, high-affinity radioligand for A(2B) receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11266650      PMCID: PMC5567772          DOI: 10.1016/s0006-2952(01)00531-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  19 in total

1.  Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors.

Authors:  X D Ji; K A Jacobson
Journal:  Drug Des Discov       Date:  1999-11

2.  Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.

Authors:  Y C Kim; M de Zwart; L Chang; S Moro; J K von Frijtag Drabbe Künzel; N Melman; A P IJzerman; K A Jacobson
Journal:  J Med Chem       Date:  1998-07-16       Impact factor: 7.446

Review 3.  Adenosine A2B receptors: a novel therapeutic target in asthma?

Authors:  I Feoktistov; R Polosa; S T Holgate; I Biaggioni
Journal:  Trends Pharmacol Sci       Date:  1998-04       Impact factor: 14.819

Review 4.  Adenosine A2B receptors.

Authors:  I Feoktistov; I Biaggioni
Journal:  Pharmacol Rev       Date:  1997-12       Impact factor: 25.468

5.  Positive modulation of intracellular Ca2+ levels by adenosine A2b receptors, prostacyclin, and prostaglandin E1 via a cholera toxin-sensitive mechanism in human erythroleukemia cells.

Authors:  I Feoktistov; J J Murray; I Biaggioni
Journal:  Mol Pharmacol       Date:  1994-06       Impact factor: 4.436

6.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

7.  Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells.

Authors:  M B Grant; R W Tarnuzzer; S Caballero; M J Ozeck; M I Davis; P E Spoerri; I Feoktistov; I Biaggioni; J C Shryock; L Belardinelli
Journal:  Circ Res       Date:  1999-10-15       Impact factor: 17.367

8.  The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist.

Authors:  S M Poucher; J R Keddie; P Singh; S M Stoggall; P W Caulkett; G Jones; M G Coll
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

9.  The A2b adenosine receptor mediates cAMP responses to adenosine receptor agonists in human intestinal epithelia.

Authors:  G R Strohmeier; S M Reppert; W I Lencer; J L Madara
Journal:  J Biol Chem       Date:  1995-02-03       Impact factor: 5.157

10.  Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.

Authors:  H O Kim; X D Ji; N Melman; M E Olah; G L Stiles; K A Jacobson
Journal:  J Med Chem       Date:  1994-09-30       Impact factor: 7.446

View more
  38 in total

1.  Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line.

Authors:  S Merighi; K Varani; S Gessi; E Cattabriga; V Iannotta; C Ulouglu; E Leung; P A Borea
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

2.  The impact of commercially available purinergic ligands on purinergic signalling research.

Authors:  J R Flanaghan; S J Roome
Journal:  Purinergic Signal       Date:  2011-10-27       Impact factor: 3.765

Review 3.  Xanthines as adenosine receptor antagonists.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2011

4.  IFN-γ Prevents Adenosine Receptor (A2bR) Upregulation To Sustain the Macrophage Activation Response.

Authors:  Heather B Cohen; Amanda Ward; Kajal Hamidzadeh; Katya Ravid; David M Mosser
Journal:  J Immunol       Date:  2015-09-09       Impact factor: 5.422

Review 5.  Adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

6.  Probing biased/partial agonism at the G protein-coupled A(2B) adenosine receptor.

Authors:  Zhan-Guo Gao; Ramachandran Balasubramanian; Evgeny Kiselev; Qiang Wei; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2014-05-20       Impact factor: 5.858

7.  Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A3 adenosine receptor antagonists.

Authors:  Jinha Yu; Philip Mannes; Young-Hwan Jung; Antonella Ciancetta; Amelia Bitant; David I Lieberman; Sami Khaznadar; John A Auchampach; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Medchemcomm       Date:  2018-10-18       Impact factor: 3.597

8.  Tritium-labeled agonists as tools for studying adenosine A2B receptors.

Authors:  Sonja Hinz; Wessam M Alnouri; Ulrich Pleiss; Christa E Müller
Journal:  Purinergic Signal       Date:  2018-05-11       Impact factor: 3.765

9.  Characterization of the A2B adenosine receptor from mouse, rabbit, and dog.

Authors:  John A Auchampach; Laura M Kreckler; Tina C Wan; Jason E Maas; Dharini van der Hoeven; Elizabeth Gizewski; Jayashree Narayanan; Garren E Maas
Journal:  J Pharmacol Exp Ther       Date:  2009-01-13       Impact factor: 4.030

10.  Recent improvements in the development of A(2B) adenosine receptor agonists.

Authors:  Pier Giovanni Baraldi; Mojgan Aghazadeh Tabrizi; Francesca Fruttarolo; Romeo Romagnoli; Delia Preti
Journal:  Purinergic Signal       Date:  2009-01-31       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.